The effect of Montecukast on Nephrotic Syndrome
Phase 3
Recruiting
- Conditions
- ephrotic Syndrome.Nephrotic syndrome
- Registration Number
- IRCT20130518013366N13
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Affected to Nephrotic Syndrome
Exclusion Criteria
Underlying blood disease
Underlying liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albumin level. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Blood test.;Urinary tract Infection. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Urine test.;Edema. Timepoint: Before treatment and 2 months after the administration of Montelukast. Method of measurement: Physical examination.
- Secondary Outcome Measures
Name Time Method